Orthopaedic Practice Consolidation: An RCM Readiness Checklist for PE-Backed Growth

If your orthopaedic group is evaluating consolidation or a private-equity partnership in 2026, revenue cycle readiness is one of the first things a sophisticated buyer will diligence, and one of the biggest drivers of your valuation. In practical terms, being RCM-ready means your net collection rate, denial rate, days in AR, and clean claim rate are strong and clearly documented; your coding is accurate and defensible; and your systems can scale without proportionally scaling headcount. This checklist walks through what buyers look for, why each metric matters to valuation, and how to close gaps before you go to market.

Why RCM readiness drives valuation in orthopaedic consolidation

Consolidation multiples are built on normalized earnings, and the revenue cycle sits directly on top of earnings. A group that leaves revenue on the table through undercoding, high denials, or slow collections is showing a buyer both a lower current EBITDA and a red flag about operational discipline.

Conversely, a group with clean, well-documented RCM performance signals that its earnings are real, durable, and improvable. This supports a higher multiple and a smoother diligence process. Buyers also value scalability: a practice whose billing costs rise in lockstep with volume is less attractive than one that has automated the revenue cycle and can absorb growth.

The RCM readiness checklist

Use the following as a pre-diligence self-assessment. Each item is something a buyer’s quality-of-earnings team will probe.

Net collection rate documented at 95%+. Be able to show, by payer and service line, that you collect the large majority of what you are owed. A rate materially below 95% invites questions about recoverable losses.

Denial rate low and trending down. Track your first-pass denial rate and demonstrate a systematic appeals process. Buyers want to see that denials are managed, not tolerated.

Days in AR and AR over 90 days in healthy ranges. Days in AR in the mid-30s to low-40s and AR over 90 days under roughly 15% show a well-run back end.

Clean claim rate at 95%+. A high first-pass clean claim rate proves front-end quality and predicts stable cash flow.

Coding accuracy and compliance. Demonstrate that your CPT, ICD-10, and modifier usage is accurate and auditable, ideally supported by tooling that stays current with AMA and CMS updates. Compliance exposure is a valuation risk buyers price in.

Scalable, low-dependency operations. Show that revenue cycle throughput does not depend on a few irreplaceable coders, and that you are not exposed to coder turnover. Automation and documented workflows de-risk the people problem.

Clean, integrated data. Buyers want reporting they can trust. Consistent metrics pulled from an EHR-integrated system beat spreadsheets assembled by hand.

Turning RCM into a valuation asset before you sell

The groups that command the best terms treat the pre-transaction window as a value-creation opportunity, not just a clean-up exercise. Recovering undercoded revenue lifts EBITDA directly. Reducing denials and shortening AR improves both earnings and the cash conversion story.

Using AI to improve coding and the revenue cycle lowers the cost-to-collect and demonstrates scalability, which is exactly the profile PE buyers reward. Many large, successful orthopaedic organizations operate at the level of RCM discipline that consolidation-minded groups aspire to.

The practical sequence is straightforward: benchmark your metrics honestly against MGMA-style targets, fix the front-end drivers of denials and undercoding first because they compound, automate the repeatable steps to prove scalability, and document everything so diligence is fast and confident.

Frequently asked questions

What RCM metrics do PE buyers care about most in orthopaedics?

Buyers focus on net collection rate, first-pass denial rate, days in AR, AR over 90 days, and clean claim rate, alongside coding accuracy and compliance. These metrics validate that reported earnings are real and that the revenue cycle can scale with growth.

How does revenue cycle performance affect valuation?

Because multiples apply to normalized earnings, revenue lost to undercoding, denials, or slow collections lowers EBITDA and raises diligence concerns. Strong, documented RCM performance supports a higher multiple and signals operational discipline and durable earnings.

Should we fix RCM problems before or after a transaction?

Before. Recovering undercoded revenue and reducing denials lifts EBITDA directly and improves the multiple applied to it, so the value created in the pre-transaction window is often far greater than the cost of the work.

How does coding automation help with consolidation readiness?

Automation reduces coding errors and denials, lowers cost-to-collect, and removes dependency on hard-to-replace coders — demonstrating the scalability buyers pay for. It also produces consistent, EHR-integrated reporting that makes diligence faster.

What days in AR and denial rate should we target before going to market?

Aim for days in AR in the mid-30s to low-40s, AR over 90 days under about 15%, a net collection and clean claim rate of 95% or higher, and a denial rate that is low and demonstrably trending down. These are directional targets that vary with payer mix and subspecialty.

See how Maia’s AutoCoder helps improve these metrics for orthopaedic practices. Book a demo at usemaia.com.